Advertisement
Canada markets close in 5 hours 28 minutes
  • S&P/TSX

    22,162.22
    +55.14 (+0.25%)
     
  • S&P 500

    5,250.63
    +2.14 (+0.04%)
     
  • DOW

    39,736.70
    -23.38 (-0.06%)
     
  • CAD/USD

    0.7378
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    82.35
    +1.00 (+1.23%)
     
  • Bitcoin CAD

    96,301.99
    +1,819.52 (+1.93%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,226.00
    +13.30 (+0.60%)
     
  • RUSSELL 2000

    2,121.28
    +6.94 (+0.33%)
     
  • 10-Yr Bond

    4.1980
    +0.0020 (+0.05%)
     
  • NASDAQ

    16,388.32
    -11.20 (-0.07%)
     
  • VOLATILITY

    13.02
    +0.24 (+1.88%)
     
  • FTSE

    7,963.02
    +31.04 (+0.39%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6825
    +0.0020 (+0.29%)
     

BriaCell Therapeutics (TSE:BCT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

Given this risk, we thought we'd take a look at whether BriaCell Therapeutics (TSE:BCT) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for BriaCell Therapeutics

Does BriaCell Therapeutics Have A Long Cash Runway?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When BriaCell Therapeutics last reported its balance sheet in January 2023, it had zero debt and cash worth US$34m. Importantly, its cash burn was US$16m over the trailing twelve months. Therefore, from January 2023 it had 2.1 years of cash runway. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is BriaCell Therapeutics' Cash Burn Changing Over Time?

Because BriaCell Therapeutics isn't currently generating revenue, we consider it an early-stage business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. Over the last year its cash burn actually increased by 32%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can BriaCell Therapeutics Raise More Cash Easily?

While BriaCell Therapeutics does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

ADVERTISEMENT

BriaCell Therapeutics' cash burn of US$16m is about 15% of its US$107m market capitalisation. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

So, Should We Worry About BriaCell Therapeutics' Cash Burn?

On this analysis of BriaCell Therapeutics' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about BriaCell Therapeutics' situation. On another note, BriaCell Therapeutics has 4 warning signs (and 3 which don't sit too well with us) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here